Current status on M. pneumoniae: Clinical Features and Management Strategies

Background: The COVID-19 pandemic has significantly impacted Mycoplasma pneumoniae (MP), leading to a decline in prevalence and delayed resurgence. The rise of macrolide-resistant M. pneumoniae complicates treatment, necessitating alternative antibiotics. Aim: This review examines the impact of...

Full description

Saved in:
Bibliographic Details
Main Authors: Asit K, Bragadeeshwaran N, Janhavi MS, Shamina S, Lavanya SV, Suria P, Muthu PP
Format: Article
Language:English
Published: Nigerian Medical Association, Akwa Ibom State Branch 2025-04-01
Series:Ibom Medical Journal
Subjects:
Online Access:http://ibommedicaljournal.org/index.php/imjhome/article/view/684
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849469765305761792
author Asit K
Bragadeeshwaran N
Janhavi MS
Shamina S
Lavanya SV
Suria P
Muthu PP
author_facet Asit K
Bragadeeshwaran N
Janhavi MS
Shamina S
Lavanya SV
Suria P
Muthu PP
author_sort Asit K
collection DOAJ
description Background: The COVID-19 pandemic has significantly impacted Mycoplasma pneumoniae (MP), leading to a decline in prevalence and delayed resurgence. The rise of macrolide-resistant M. pneumoniae complicates treatment, necessitating alternative antibiotics. Aim: This review examines the impact of COVID-19 on M. pneumoniae (MP) epidemiology, rising macrolide resistance, and evolving treatment challenges. It highlights advanced diagnostics, alternative antibiotics, and future research needs for predictive biomarkers and novel therapies. Continuous surveillance and adaptive strategies are crucial for optimizing MP infection management in a post-pandemic world. Methods: A comprehensive review of recent literature was conducted, focusing on epidemiological trends, antimicrobial resistance patterns, diagnostic innovations, and treatment strategies for MP infections. Data were extracted from peer-reviewed journals, clinical studies, and global health reports to provide an updated perspective on the evolving landscape of MP infections. Results: M. pneumoniae infections, which declined during COVID-19 due to non-pharmaceutical interventions, have resurged post-pandemic due to macrolide-resistant infections. Rapid molecular diagnostic tools and predictive biomarkers are needed to improve treatment outcomes and optimize infection management in pediatric patients. Conclusion: Managing MP infections in a post-pandemic world requires continuous surveillance, advanced diagnostics, and adaptive treatment strategies. The increasing prevalence of MRMP underscores the need for alternative therapeutic options and robust antimicrobial stewardship. Future research should focus on predictive factors for treatment response, novel drug development, and the long-term impact of epidemiological shifts on respiratory infections.
format Article
id doaj-art-e80ed4d4a2ac41d8ac8d00f494c3b89d
institution Kabale University
issn 1597-7188
2735-9964
language English
publishDate 2025-04-01
publisher Nigerian Medical Association, Akwa Ibom State Branch
record_format Article
series Ibom Medical Journal
spelling doaj-art-e80ed4d4a2ac41d8ac8d00f494c3b89d2025-08-20T03:25:22ZengNigerian Medical Association, Akwa Ibom State BranchIbom Medical Journal1597-71882735-99642025-04-0118210.61386/imj.v18i2.684Current status on M. pneumoniae: Clinical Features and Management StrategiesAsit K0Bragadeeshwaran N1Janhavi MS2Shamina S3Lavanya SV4Suria P5Muthu PP6Department of Environmental Science, Rajdhani College (University of Delhi), Raja Garden, New Delhi- 110015Department of Paediatrics, Velammal Medical College and research institute, Madurai-625009Department of Pathology, Sree Balaji Medical College and Hospital, ChennaiDepartment of Biochemistry, RVS College of Arts and Science, Sulur Coimbatore-641402ACS Medical college and hospital, Dr.M.G.R. Educational and Research Institute, Maduravoyal, ChennaiDepartment of Pharmaceutical Sciences Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam – 603103, Tamil Nadu, IndiaDepartment of Pharmaceutical, Biotechnology, Surya college of Pharmacy, India Background: The COVID-19 pandemic has significantly impacted Mycoplasma pneumoniae (MP), leading to a decline in prevalence and delayed resurgence. The rise of macrolide-resistant M. pneumoniae complicates treatment, necessitating alternative antibiotics. Aim: This review examines the impact of COVID-19 on M. pneumoniae (MP) epidemiology, rising macrolide resistance, and evolving treatment challenges. It highlights advanced diagnostics, alternative antibiotics, and future research needs for predictive biomarkers and novel therapies. Continuous surveillance and adaptive strategies are crucial for optimizing MP infection management in a post-pandemic world. Methods: A comprehensive review of recent literature was conducted, focusing on epidemiological trends, antimicrobial resistance patterns, diagnostic innovations, and treatment strategies for MP infections. Data were extracted from peer-reviewed journals, clinical studies, and global health reports to provide an updated perspective on the evolving landscape of MP infections. Results: M. pneumoniae infections, which declined during COVID-19 due to non-pharmaceutical interventions, have resurged post-pandemic due to macrolide-resistant infections. Rapid molecular diagnostic tools and predictive biomarkers are needed to improve treatment outcomes and optimize infection management in pediatric patients. Conclusion: Managing MP infections in a post-pandemic world requires continuous surveillance, advanced diagnostics, and adaptive treatment strategies. The increasing prevalence of MRMP underscores the need for alternative therapeutic options and robust antimicrobial stewardship. Future research should focus on predictive factors for treatment response, novel drug development, and the long-term impact of epidemiological shifts on respiratory infections. http://ibommedicaljournal.org/index.php/imjhome/article/view/684Clinical featuresDiagnostic advancesM. pneumoniaManagement strategiestreatment protocols
spellingShingle Asit K
Bragadeeshwaran N
Janhavi MS
Shamina S
Lavanya SV
Suria P
Muthu PP
Current status on M. pneumoniae: Clinical Features and Management Strategies
Ibom Medical Journal
Clinical features
Diagnostic advances
M. pneumonia
Management strategies
treatment protocols
title Current status on M. pneumoniae: Clinical Features and Management Strategies
title_full Current status on M. pneumoniae: Clinical Features and Management Strategies
title_fullStr Current status on M. pneumoniae: Clinical Features and Management Strategies
title_full_unstemmed Current status on M. pneumoniae: Clinical Features and Management Strategies
title_short Current status on M. pneumoniae: Clinical Features and Management Strategies
title_sort current status on m pneumoniae clinical features and management strategies
topic Clinical features
Diagnostic advances
M. pneumonia
Management strategies
treatment protocols
url http://ibommedicaljournal.org/index.php/imjhome/article/view/684
work_keys_str_mv AT asitk currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT bragadeeshwarann currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT janhavims currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT shaminas currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT lavanyasv currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT suriap currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies
AT muthupp currentstatusonmpneumoniaeclinicalfeaturesandmanagementstrategies